| Literature DB >> 24900728 |
Miki Matsuo1, Asami Hasegawa1, Masashi Takano1, Hiroshi Saito2, Shinji Kakuda2, Takayuki Chida2, Ken-Ichiro Takagi2, Eiji Ochiai2, Kyohei Horie2, Yoshifumi Harada2, Midori Takimoto-Kamimura2, Kazuya Takenouchi2, Daisuke Sawada1, Atsushi Kittaka1.
Abstract
2α-Heteroarylethyl-1α,25-dihydroxyvitamin D3 analogues, which were designed to form a hydrogen bond between Arg274 of human vitamin D receptor (hVDR) and a nitrogen atom of the heteroaromatic ring at the 2α-position, were synthesized. Among them, 2α-[2-(tetrazol-2-yl)ethyl]-1α,25-dihydroxyvitamin D3 showed higher osteocalcin promoter transactivation activity in human osteosarcoma (HOS) cells and a greater therapeutic effect in ovariectomized (OVX) rats, osteoporosis model animals, on enhancing bone mineral density than those of active vitamin D3. X-ray cocrystallographic analysis of the hVDR-ligand complex confirms that the new hydrogen bond formation stabilized the complex.Entities:
Keywords: Vitamin D; X-ray cocrystallographic analysis; bone mineral density; in vivo antiosteoporotic effect; osteocalcin; vitamin D receptor
Year: 2013 PMID: 24900728 PMCID: PMC4027143 DOI: 10.1021/ml400098w
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345